Shine Technologies, an advanced nuclear technology company and producer of lutetium-177, entered into a long-term supply agreement with Nucleus RadioPharma, a company involved in the development, manufacturing, and supply chain organization for radiopharmaceuticals. Under the multi-year agreement, SHINE will provide lutetium-177 to Nucleus RadioPharma’s radioligand therapy (RLT) offerings for targeted radiopharmaceutical treatments for neuroendocrine tumors and prostate cancer. The p...